Advertisement

Nitric Oxide

  • Emily L. Dobyns
  • Eva N. Grayck
Chapter

Keywords

Nitric Oxide Nitric Oxide Pulmonary Hypertension Acute Respiratory Distress Syndrome Primary Pulmonary Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288(5789):373–376.PubMedCrossRefGoogle Scholar
  2. 2.
    Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327(6122):524–526.PubMedCrossRefGoogle Scholar
  3. 3.
    Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84(24):9265–9269.PubMedCrossRefGoogle Scholar
  4. 4.
    Stuehr DJ, Gross SS, Sakuma I, Levi R, Nathan CF. Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp Med 1989;169(3):1011–1020.PubMedCrossRefGoogle Scholar
  5. 5.
    Snyder SH. Nitric oxide: first in a new class of neurotransmitters. Science 1992;257(5069):494–496.PubMedCrossRefGoogle Scholar
  6. 6.
    Bruckdorfer R. The basics about nitric oxide. Mol Aspects Med 2005;26(1–2):3–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Tatoyan A, Giulivi C. Purification and characterization of a nitric-oxide synthase from rat liver mitochondria. J Biol Chem 1998;273(18):11044–11048.PubMedCrossRefGoogle Scholar
  8. 8.
    Schild L, Reinheckel T, Reiser M, Horn TF, Wolf G, Augustin W. Nitric oxide produced in rat liver mitochondria causes oxidative stress and impairment of respiration after transient hypoxia. FASEB J 2003;17(15):2194–2201.PubMedCrossRefGoogle Scholar
  9. 9.
    Kone BC. Nitric oxide synthesis in the kidney: isoforms, biosynthesis, and functions in health. Semin Nephrol 2004;24(4):299–315.PubMedCrossRefGoogle Scholar
  10. 10.
    Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357(Pt 3):593–615.PubMedCrossRefGoogle Scholar
  11. 11.
    Kone BC, Kuncewicz T, Zhang W, Yu ZY. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol 2003;285(2):F178–F190.PubMedGoogle Scholar
  12. 12.
    Pritchard KA Jr, Ackerman AW, Gross ER, Stepp DW, Shi Y, Fontana JT, et al. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem 2001;276(21):1762–1764.CrossRefGoogle Scholar
  13. 13.
    Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43(3):542–548.PubMedCrossRefGoogle Scholar
  14. 14.
    Kone BC. Protein-protein interactions controlling nitric oxide synthases. Acta Physiol Scand 2000;168(1):27–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287(4):L656–L664.PubMedCrossRefGoogle Scholar
  16. 16.
    Greenacre SA, Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 2001;34(6):541–581.PubMedCrossRefGoogle Scholar
  17. 17.
    Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005;6(2):150–166.PubMedCrossRefGoogle Scholar
  18. 18.
    Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol Med 2003;9(4):160–168.PubMedCrossRefGoogle Scholar
  19. 19.
    Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005;115(3):509–517.PubMedGoogle Scholar
  20. 20.
    Gaston BM, Carver J, Doctor A, Palmer LA. S-nitrosylation signaling in cell biology. Mol Intervent 2003;3(5):253–263.CrossRefGoogle Scholar
  21. 21.
    McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, et al. Nitric oxide in the human respiratory cycle. Nat Med 2002;8(7):711–717.PubMedGoogle Scholar
  22. 22.
    Stamler JS. S-nitrosothiols in the blood: roles, amounts, and methods of analysis. Circ Res 2004;94(4):414–417.PubMedCrossRefGoogle Scholar
  23. 23.
    Gaston B, Sears S, Woods J, Hunt J, Ponaman M, McMahon T, et al. Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet 1998;351(9112):1317–1319.PubMedCrossRefGoogle Scholar
  24. 24.
    Grasemann H, Gaston B, Fang K, Paul K, Ratjen F. Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. J Pediatr 1999;135(6):770–772.PubMedCrossRefGoogle Scholar
  25. 25.
    Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83(6):2038–2047.PubMedGoogle Scholar
  26. 26.
    Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338(8776):1173–1174.PubMedCrossRefGoogle Scholar
  27. 27.
    Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 2004;109(25):3106–3111.PubMedCrossRefGoogle Scholar
  28. 28.
    Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340(8823):819–820.PubMedCrossRefGoogle Scholar
  29. 29.
    Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340(8823):818–819.PubMedCrossRefGoogle Scholar
  30. 30.
    Kinsella JP, Neish SR, Ivy DD, Shaffer E, Abman SH. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr 1993;123(1):103–108.PubMedCrossRefGoogle Scholar
  31. 31.
    Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336(9):597–604.CrossRefGoogle Scholar
  32. 32.
    Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997;131(1 Pt 1):55–62.PubMedGoogle Scholar
  33. 33.
    Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328(6):399–405.PubMedCrossRefGoogle Scholar
  34. 34.
    Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999;25(9):911–919.PubMedCrossRefGoogle Scholar
  35. 35.
    Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998;26(1):15–23.PubMedCrossRefGoogle Scholar
  36. 36.
    Abman SH, Griebel JL, Parker DK, Schmidt JM, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994;124(6):881–888.PubMedCrossRefGoogle Scholar
  37. 37.
    Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, et al. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr 1999;134(4):406–412.PubMedCrossRefGoogle Scholar
  38. 38.
    Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, Moriguchi J, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001;72(4):638–641.PubMedCrossRefGoogle Scholar
  39. 39.
    Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351(14):1425–1436.PubMedCrossRefGoogle Scholar
  40. 40.
    Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993;87(2):440–446.PubMedGoogle Scholar
  41. 41.
    Roberts JD, Jr., Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993;87(2):447–453.PubMedGoogle Scholar
  42. 42.
    Goldman AP, Delius RE, Deanfield JE, Miller OI, de Leval MR, Sigston PE, et al. Pharmacological control of pulmonary blood flow with inhaled nitric oxide after the fenestrated Fontan operation. Circulation 1996;94(9 Suppl):II44–II48.PubMedGoogle Scholar
  43. 43.
    Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congen-ital heart surgery: a randomised double-blind study. Lancet 2000;356(9240):1464–1469.PubMedCrossRefGoogle Scholar
  44. 44.
    Fox-Robichaud A, Payne D, Hasan SU, Ostrovsky L, Fairhead T, Reinhardt P, et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 1998;101(11):2497–2505.PubMedCrossRefGoogle Scholar
  45. 45.
    Date H, Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996;111(5):913–919.PubMedCrossRefGoogle Scholar
  46. 46.
    Ardehali A, Laks H, Levine M, Shpiner R, Ross D, Watson LD, et al. A prospective trial of inhaled nitric oxide in clinical lung transplantation. Transplantation 2001;72(1):112–115.PubMedCrossRefGoogle Scholar
  47. 47.
    Meade MO, Granton JT, Matte-Martyn A, McRae K, Weaver B, Cripps P, et al. A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003;167(11):1483–1489.PubMedCrossRefGoogle Scholar
  48. 48.
    Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998;32(4):1068–1073.PubMedCrossRefGoogle Scholar
  49. 49.
    Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, et al. Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation 2002;106(12 Suppl 1):I76–I81.PubMedGoogle Scholar
  50. 50.
    Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12(2):265–270.PubMedCrossRefGoogle Scholar
  51. 51.
    Ivy DD, Parker D, Doran A, Kinsella JP, Abman SH. Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension. Am J Cardiol 2003;92(7):886–890.PubMedCrossRefGoogle Scholar
  52. 52.
    Dobyns EL, Griebel J, Kinsella JP, Abman SH, Accurso FJ. Infant lung function after inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 1999;28(1):24–30.PubMedCrossRefGoogle Scholar
  53. 53.
    Rosenberg AA, Kennaugh JM, Moreland SG, Fashaw LM, Hale KA, Torielli FM, et al. Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension. J Pediatr 1997;131(1 Pt 1):70–75.PubMedGoogle Scholar
  54. 54.
    Dobyns EL, Anas NG, Fortenberry JD, Deshpande J, Cornfield DN, Tasker RC, et al. Interactive effects of high-frequency oscillatory ventilation and inhaled nitric oxide in acute hypoxemic respiratory failure in pediatrics. Crit Care Med 2002;30(11):2425–2429.PubMedCrossRefGoogle Scholar
  55. 55.
    Kinsella JP, Abman SH. High-frequency oscillatory ventilation augments the response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn: Nitric Oxide Study Group. Chest 1998;114(1 Suppl):100S.PubMedCrossRefGoogle Scholar
  56. 56.
    Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, et al. Safety of withdrawing inhaled nitric oxide therapy in per-sistent pulmonary hypertension of the newborn. Pediatrics 1999;104(2 Pt 1):231–236.PubMedCrossRefGoogle Scholar
  57. 57.
    Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998;115(4):875–882.PubMedCrossRefGoogle Scholar
  58. 58.
    Oka M, Ohnishi M, Takahashi H, Soma S, Hasunuma K, Sato K, et al. Altered vasoreactivity in lungs isolated from rats exposed to nitric oxide gas. Am J Physiol 1996;271(3 Pt 1):L419–L424.PubMedGoogle Scholar
  59. 59.
    Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003;108(2):239–244.PubMedCrossRefGoogle Scholar
  60. 60.
    Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360(9337):895–900.PubMedCrossRefGoogle Scholar
  61. 61.
    Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105(20):2398–2403.PubMedCrossRefGoogle Scholar
  62. 62.
    Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343(18):1342.PubMedCrossRefGoogle Scholar
  63. 63.
    Synder AH, McPherson ME, Hunt JF, Johnson M, Stanker JS, Gaston B. Acute effects of aerosolized S-nitrosogluathione in cystic fibrosis. Am J Respir Crit Care Med 2002:165(7):922–926.Google Scholar
  64. 64.
    Moya MP, Gow AJ, Califf RM, Goldberg RN, Stamler JS. Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. Lancet 2002:360(9327):141–143.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2009

Authors and Affiliations

  • Emily L. Dobyns
    • 1
  • Eva N. Grayck
    • 2
  1. 1.Division of Critical Care Medicine The Children’s Hospital DenverUniversity of Colorado Health Sciences CenterDenverUSA
  2. 2.Division of Critical Care Medicine The Children’s Hospital DenverUniversity of Colorado Health Sciences CenterDenverUSA

Personalised recommendations